激肽释放酶增强凝血酶生成中蛋白C系统的抗凝功能
研究利用392名人类功能基因组计划参与者的血浆,检测组织因子触发的凝血酶生成及血栓调节蛋白调节的凝血酶生成,并做全基因组SNP分型。发现KLKB1基因(top SNP rs4241819)与nETP-TMsr在全基因组水平相关(P=4.27×10-8),体外补充激肽释放酶(非前激肽释放酶或载脂蛋白A-IV)剂量依赖性增强TM和APC的抗凝效果。
要点
- KLKB1基因rs4241819与血栓调节蛋白调节的凝血酶生成敏感性相关。
- 激肽释放酶可剂量依赖性增强TM和APC在凝血酶生成中的抗凝作用。
- 该关联在接触途径抑制剂存在时消失,提示接触途径参与。
核心结论
- 激肽释放酶参与凝血酶生成中蛋白C通路的抗凝调节,可能解释KLKB1基因与静脉血栓的关联。
研究设计与样本
- 研究纳入人类功能基因组计划392名参与者的血浆,测量有无TM时的校准凝血酶生成,并进行全基因组SNP分型。
- 体外补充纯化的载脂蛋白A-IV、前激肽释放酶或激肽释放酶,检测其对TM和APC抗凝功能的影响。
主要发现
- KLKB1基因top SNP rs4241819与nETP-TMsr在全基因组水平相关(P=4.27×10-8)。
- 体外补充激肽释放酶(而非前激肽释放酶或载脂蛋白A-IV)剂量依赖性增强TM和APC在凝血酶生成中的抗凝效果。
- rs4241819变异与前激肽释放酶血浆浓度无关。
- 在接触途径抑制剂存在时,rs4241819与nETP-TMsr的关联消失。
关键数值与推荐
- 全基因组关联分析中,KLKB1基因rs4241819与nETP-TMsr达到全基因组显著性(P=4.27×10-8)。
- 体外实验显示激肽释放酶剂量依赖性增强TM和APC的抗凝效果,但原文未报告具体剂量或效应值。
临床怎么用
- 提示KLKB1/激肽释放酶-蛋白C轴可能作为血栓风险评价的潜在靶点,但尚需临床验证。
局限性
- 研究为体外血浆实验,样本量392人,结论需进一步体内研究验证。
- 原文未报告激肽释放酶增强抗凝作用的具体分子机制及临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetics play a significant role in coagulation phenotype and venous thromboembolism risk. Resistance to the anticoagulant activated protein C (APC) is an established risk for thrombosis. Herein, we explored the genetic determinants of thrombin generation (TG) and thrombomodulin (TM)-modulated TG using plasma from the Human Functional Genomics Project. METHODS: Calibrated TG was measured both in absence and presence of TM using tissue factor as trigger. Genetic determinants of TG parameters and protein C pathway function were assessed using genome-wide single-nucleotide polymorphism (SNP) genotyping. Plasma samples were supplemented with purified apolipoprotein A-IV, prekallikrein, or kallikrein to test their influence on the anticoagulant function of TM and APC in TG. RESULTS: Thrombin generation data from 392 individuals were analyzed. Genotyping showed that the KLKB1 gene (top SNP: rs4241819) on chromosome 4 was associated with the normalized sensitivity ratio of endogenous thrombin potential to TM at genome-wide level (nETP-TMsr, P = 4.27 × 10-8 ). In vitro supplementation of kallikrein, but not prekallikrein or apolipoprotein A-IV, into plasma dose-dependently augmented the anticoagulant effect of TM and APC in TG. Variations of rs4241819 was not associated with the plasma concentration of prekallikrein. Association between rs4241819 and nETP-TMsr was absent when TG was measured in presence of a contact pathway inhibitor corn trypsin inhibitor. CONCLUSIONS: Our results suggest that kallikrein plays a role in the regulation of the anticoagulant protein C pathway in TG, which may provide a novel mechanism for the previously observed association between the KLKB1 gene and venous thrombosis.
引用
- Wan J, Vadaq N, Konings J, et al. Kallikrein augments the anticoagulant function of the protein C system in thrombin generation. J Thromb Haemost. 2021. PMID: 34532976. doi:10.1111/jth.15530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。